The global atherosclerosis drugs market is expected to grow at a significant CAGR during the forecast period (2021-2027). The rise in the prevalence of atherosclerosis and cardiovascular disorders is a major factor driving the market’s growth. According to the European Heart Network, cardiovascular disease kills 3.9 million people in Europe each year, with over 1.8 million people dying in the European Union. In wealthy countries, sedentary lifestyles are responsible for the highest rates of cardiovascular disease. Sedentary behaviour is associated with a high prevalence of high blood pressure, high cholesterol, obesity, and excessive alcohol intake, all of which contribute to an increased risk of cardiovascular disease. As a result, the market examined is predicted to be driven by a sedentary lifestyle resulting in a high prevalence of cardiovascular illnesses and rising awareness of treatment choices.
Statins and fibrates are two types of cholesterol-lowering medicines. The growing prevalence of cardiovascular disease, high cholesterol, and obesity globally is responsible for the segment’s dominance. In 2018, the World Health Organization (WHO) predicted that 40 million children under the age of five were overweight or obese. Increased consumption of high-fat, high-sugar foods, as well as an increase in physical immobility due to the increasingly inactive nature of many types of work, changing modes of transportation, and increasing urbanization, are all contributing to high cholesterol rates and, as a result, segment growth.
To Request a Sample of our Report on Global Atherosclerosis Drugs Market: https://www.omrglobal.com/request-sample/atherosclerosis-drugs-market
In addition, the approval of new cholesterol-lowering medications is boosting the market growth. For instance, the pharmaceuticals alirocumab (Praluent) and evolocumab (Repatha) are part of a novel class of treatments known as PCSK9 inhibitors, which reduce dangerous LDL cholesterol levels by more than 50%. Novel therapeutic medications like this help to drive segment growth. The segment’s growth is aided by an expanding patient pool and increased approvals of new medications.
Market Coverage
· The market number available for – 2020-2027
· Base year- 2020
· Forecast period- 2021-2027
· Segment Covered
· Regions Covered- Globally
· Competitive Landscape: Pfizer Inc., AstraZeneca, Merck & Co., Inc., Sanofi US, among others.
(Get 15% Discount on Buying this Report)
A full Report of Global Atherosclerosis Drugs Market is Available at: https://www.omrglobal.com/industry-reports/atherosclerosis-drugs-market
Global Atherosclerosis Drugs Market by Segments
By Drug Class
• Anti-Platelet Medications
• Cholesterol-Lowering Medications
• Fibric Acid and Omega-3 Fatty Acid Derivatives
• Beta Blockers
• Others
By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
Global Atherosclerosis Drugs Market by Region
North America
· United States
· Canada
Europe
· UK
· Germany
· Spain
· France
· Italy
· Rest of Europe
Asia-Pacific
· India
· China
· Japan
· South Korea
· Rest of APAC
Rest of the World
Reasons to buy from us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
